Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) - BioSpace

Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)  BioSpace

Published: Jun 24, 2019. STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty ...



Comments

Popular posts from this blog

Different types of doctors in South Africa and their salaries 2022 - Briefly

Ebstein's Anomaly: Symptoms, Causes, and Treatments - Verywell Health

Internal vs. Family Medicine: Who's Who in Primary Care - Avera Health